Benjamin Cooper, MD, Remarks on Future Analyses of TAK-676 Plus Pembrolizumab in Solid Tumors Undergoing Radiation


Benjamin Cooper, MD, discussed potential future studies exploring TAK-676 plus pembrolizumab after radiation for those with solid tumors.

Benjamin Cooper, MD, a radiation oncologist and director of Proton Therapy Services at NYU Langone Health, spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about TAK-676 plus pembrolizumab (Keytruda) after radiation for patients with non–small cell lung, triple-negative breast, and squamous cell head and neck cancer. In this phase 1 trial in progress (NCT04879849), Cooper noted his desire to investigate this protocol in patients with oligometastatic cancer.


The interesting part about this trial is the addition of radiation therapy. If this is a positive result and we can show the safety of combining radiation therapy, checkpoint inhibition, and sting agonists, we will hopefully be able to expand this to other indications such as oligoprogression, potentially other oligometastatic cases, and even other tumor types.

We hope that people are interested in this trial and that we can help generate some patient interest so we can determine the appropriate dose of this drug. By looking at some of the correlative biomarkers, we’ll find any other new pathways or new approaches to help these patients with progressing cancer.


Cooper BT, Chmura SJ, Luke JJ, et al. TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design. J Clin Oncol. 2022;40(suppl 17):TPS2698. doi: 10.1200/JCO.2022.40.16_suppl.TPS2698

Related Videos
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.
Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.
While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.
Recommendations penned by the American Society of Clinical Oncology and Society for Gynecologic Oncology may be critical in managing the ongoing chemotherapy shortage, according to Michael Ganio, PharmD, MS, BCPS, FASHP.
Chemotherapy agents imported from Chinese manufacturers may have barcodes that don’t work or be missing an NDC number, according to Michael Ganio, PharmD, MS, BCPS, FASHP.
Results of a survey from the National Comprehensive Cancer Network indicate that almost all responding institutions are experiencing a carboplatin shortage.
Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
Related Content